New Zealand’s world-first combination analgesic

AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibuprofen to provide superior pain relief to patients than either agent on its own.

AFT will supply Maxigesic® in NZ and Australia and is looking for a partner to sell the drug overseas. The global pain relief market is worth $27 billion a year and group CEO Dr Hartley Atkinson sees massive potential for this product to take a good share of that.

July 23, 2026

Pitt St Research initiates coverage on AFT Pharmaceuticals

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that Pitt St Research has initiated coverage on AFT Pharmaceuticals Ltd….

Read More

May 21, 2026

AFT delivers double digit revenue growth and record earnings

Operating profit or $24.4 million ahead of the guidance range….

Read More

May 18, 2026

AFT Pharmaceuticals names Stuart Houliston CFO

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises that Stuart Houliston will commence …

Read More